IL-2 is a 133-amino-acid immune growth factor that can dramatically boost cancer-killing immune cells, but early clinical trials showed severe side effects at high doses.
133 amino acidsThe complete IL-2 protein — one of the most potent immune activators known
What the researchers found
IL-2 is a 133-amino acid protein (molecular weight 15,420 daltons) produced by activated T-cells. Its gene sits on chromosome 4. The IL-2 receptor is a 272-amino acid protein (55,000 daltons).
IL-2 does not just make immune cells copy themselves. It moves cells from a resting state (G1) through to DNA synthesis (S phase). During this process, the proto-oncogene c-myb increases 6 to 7 times above normal levels.
The most exciting clinical development: IL-2 could expand LAK cells (lymphokine-activated killer cells) and TIL (tumor-infiltrating lymphocytes) that attack cancer. Early human trials showed both therapeutic promise and significant toxicity.
Thymosin fraction 5 and thymosin alpha 1 could modulate IL-2 receptor expression on human blood cells, potentially increasing the effectiveness of IL-2 therapy.
Why it matters
This review captured a pivotal moment in cancer immunotherapy. IL-2 was about to become the first immunotherapy approved for cancer (FDA approved in 1992 for kidney cancer). The connection to thymosin alpha 1 as an IL-2 receptor enhancer suggested combination approaches that are still studied today.
How the study worked
Narrative review covering IL-2 research from 1984 to September 1986. Covered molecular biology, mechanism of action, cell biology, disease associations, animal models, early clinical trials, and interaction with thymosin peptides.
What this study cannot tell us
As a 1987 review, much of the clinical data was preliminary. The toxicity of IL-2 therapy proved to be a major limitation in practice. The thymosin-IL-2 combination was promising but not yet clinically tested.
How to read the evidence
Moderate — comprehensive review of molecular biology and early-phase clinical data.
When this study was published
Published in 1987 — IL-2 has since been FDA-approved for certain cancers, validating the early research reviewed here.
The bigger picture
IL-2 became one of the first approved cancer immunotherapies. Understanding its biology paved the way for modern checkpoint inhibitors and adoptive cell therapy.
Questions still open
- Can thymosin alpha 1 reduce IL-2 side effects while maintaining efficacy?
- What is the optimal IL-2 dosing schedule for cancer?
Common questions
What is IL-2?
Why is IL-2 combined with other treatments?
Read the original research
Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2.
Lymphokine research, 6(1), 45-57
Citation
Fletcher, M; Goldstein, A L. (1987). Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2.. Lymphokine research, 6(1), 45-57.